Skip to main content
Premium Trial:

Request an Annual Quote

Axys, Roche Bioscience Enter Genomics Alliance

Premium

PALO ALTO, Calif.--Drug discovery company Roche Biosciences here announced it has formed an alliance with Axys Pharmaceuticals of South San Francisco, Calif., to utilize Axys's functional genomics capabilities. Axys will apply its technologies utilizing C. elegans to evaluate the function of genes provided by Roche that may serve as drug targets in the development of therapies for pain and other nervous system disorders.

Roche will pay Axys an upfront fee and provide funding for research support. Axys has granted Roche an option to license targets discovered during the collaboration for the development of small molecule, diagnostic, and antisense products, with license payments, milestones, and royalties payable to Axys. Axys may also retain rights to develop gene therapy and therapeutic protein products acting upon targets discovered during the collaboration.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.